Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PLX7486 + unspecified CTLA4 antibody |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PLX7486 | PLX 7486|PLX-7486 | CSF1R Inhibitor 28 Trk Receptor Inhibitor (Pan) 33 | PLX7486 binds to and inhibits CSF1R, TRKA, TRKB, and TRKC, which potentially results in decreased tumor cell proliferation (PMID: 28174090). | |
| unspecified CTLA4 antibody | experimental CTLA4 antibody | Immune Checkpoint Inhibitor 150 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NTRK1 positive | colon adenocarcinoma | predicted - sensitive | PLX7486 + unspecified CTLA4 antibody | Preclinical - Cell line xenograft | Actionable | In a preclinical study, combination of PLX7486 and anti-CTLA4 immunotherapy resulted in enhanced anti-tumor effect compared to single therapy in animal models of Ntrk-positive colon adenocarcinoma (Cancer Immunol Res 2017;5(3 Suppl): Abstract nr PR01). | detail... |
| NTRK1 positive | melanoma | predicted - sensitive | PLX7486 + unspecified CTLA4 antibody | Preclinical - Cell line xenograft | Actionable | In a preclinical study, combination of PLX7486 and anti-CTLA4 immunotherapy resulted in enhanced anti-tumor effect compared to single therapy in animal models of Ntrk-positive melanoma (Cancer Immunol Res 2017;5(3 Suppl): Abstract nr PR01). | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|